A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Macitentan (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 27 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 26 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Nov 2016.